Key Takeaways
- Amoéba and Koppert have extended their distribution agreement for Amoéba’s biofungicide technology by one year, through June 2031.
- The agreement covers TIAGAN, aimed at vineyards, and YAZU, aimed at vegetable crops, across 18 European countries and the United States.
- The extension follows France’s marketing authorization for Amoéba’s AXPERA biofungicide, granted by ANSES at the end of June 2026.
- Koppert placed its first commercial order for Amoéba-based products in early March 2026, ahead of launches showcased at trade shows including GreenTech Europe in Amsterdam.
- Amoéba says it remains the only company authorized to produce the Willaertia amoeba industrially at commercial scale for biocontrol use.
Amoéba and Koppert Extend Biofungicide Distribution Agreement
Amoéba, a French greentech company that develops natural microbiological crop protection solutions, announced on July 23, 2026 that it extended its distribution agreement with Koppert, a global supplier of biological crop protection and pollination products, through June 2031 — a one-year extension.
The agreement covers Amoéba’s biofungicide technology across 18 European countries and the United States, spanning vineyard and vegetable crop segments.
TIAGAN and YAZU Head to Market
Koppert has been rolling out two products built on Amoéba’s technology: TIAGAN for vineyards and YAZU for vegetable growers, both featured at trade shows this year, including GreenTech Europe in Amsterdam in June. Koppert placed its first order for the products in early March 2026, a step Amoéba said signaled accelerating commercial launches. The extension follows France’s marketing authorization for the AXPERA biofungicide at the end of June, a decision the companies said points toward further approvals across Europe.
Partners React to the Extension
“We are eager to bring this breakthrough solution to market as soon as possible, given the high level of demand,” said Martin Koppert, Chief Product Officer at Koppert. “We are also very pleased that Amoéba has received approval to commercialize its biofungicide in France. This represents an important milestone for the partnership and an encouraging step towards broader market access in Europe. These developments reinforce our commitment to the successful introduction of TIAGAN and YAZU. By extending our agreement by one year, we are reaffirming our long-term commitment to this partnership and our shared ambition to make this innovative solution available to growers.”
“We are delighted that our partner Koppert has once again placed its trust in us,” said Benoit Villers, Chairman of Amoéba. “They have been working alongside us for over a year to ensure the best possible commercial development of our solution across the targeted crops and countries. We look forward to providing farmers with this groundbreaking and environmentally friendly solution.”
Amoéba’s Regulatory Path Forward
Amoéba holds patents on the industrial use of the Willaertia amoeba and says it remains the only company authorized to produce the organism at commercial scale for biocontrol and cosmetic use. The AXPERA active substance was approved in the United States in 2022 and received a positive final report from the European Food Safety Authority ahead of this year’s French authorization. The company, listed on Euronext Growth under the ticker ALMIB, said it continues to pursue approvals in additional European markets covered by the Koppert agreement.
